# Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

> **NCT02499783** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 205 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** adalimumab
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT02499783
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-17
- **Primary completion:** 2017-05-19
- **Final completion:** 2017-12-15
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499783, "Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02499783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*